Premium
microRNA‐802 accelerates hepatocellular carcinoma growth by targeting RUNX3
Author(s) -
Ni Min,
Zhao Yi,
Zhang WenJing,
Jiang YuJie,
Fu Hui,
Huang Fang,
Li DongJie,
Shen FuMing
Publication year - 2020
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.29611
Subject(s) - microrna , hepatocellular carcinoma , cell growth , cancer research , in vivo , downregulation and upregulation , transfection , cell cycle , western blot , in vitro , cell , biology , cell culture , gene , biochemistry , genetics
Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. Prognosis is often unfavorable. In this study, the effects of microRNA‐802 (miR‐802) on HCC progression were assessed in vivo and in vitro. miR‐802 was found to be significantly upregulated in HCC tumor tissue compared to paired adjacent nontumor tissue. In vitro, transfection with a miR‐802 mimic accelerated SMMC‐7721 cellular proliferation, increased accumulation of the cell‐cycle S‐phase cell populations, as well as cell migration. In vivo injection of a miR‐802 agomir promoted HCC proliferation in nude mice. Targets of miR‐802 were predicted by miRWalk, miRanda, RNA22, and Targetscan. By luciferase reporter assay RUNX3 was identified as a direct target of miR‐802. As judged by western blot analysis, RUNX3 was upregulated when miR‐802 was inhibited. These data demonstrate increased miR‐802 expression in patients with HCC and that miR‐802 overexpression promotes tumor cell growth, in a RUNX3 ‐dependent manner.